Charles River Laboratories (United States)

Charles River Laboratories (United States)

Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Charles River Laboratories (United States), United States, covering academic research published from 2000 to 2023. Read More.


Open Access Percentage

53%


Total
Publications

2.1K


Total Open
Publications

1.1K


Total
Citations

31K


Open Access
Percentage

53%


Total
Publications

2.1K


Total Open
Publications

1.1K


Total
Citations

31K

Wikipedia

Website

download

Breakdown

26% 18% 9% 47%

Publisher Open

26%

Both

18%

Other Platform Open

9%

Closed

47%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

020406080100120140160180200220240Total Publications
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

24%OA Journal

OA Journal 24%

219

Hybrid 28%

262

No Guarantees 48%

451

Other Platform Open

Domain 79%

450

Institution 27%

151

Preprint 13%

73

Public 8%

46

Other Internet 8%

43

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
444
Europe PMC
Domain
252
bioRxiv
Preprint
36
Semantic Scholar
Public
35
DOI
Other Internet
25
University College London - UCL Discovery
Institution
19
University of Cambridge - Apollo
Institution
17
Research Square
Preprint
15
University of Dundee - Discovery Research Portal
Institution
14
DANS - Data Archiving and Networked Services - NARCIS - National Academic Research and Collaborations Information System
Institution
14
1 / 13

Data updated 13 May 2024

Share

Share

Share